Case Analysis – Merck Medco Merck was a pharmaceutical manufacturer while Medco Cost Containment Services was a pharmacy benefit manager (PBM). On November 18th, 1993, Merck purchased Medco for $6.6 billion. Immediately after this merger, Medco operated as a subsidiary of Merck. This acquisition of Medco by Merck is a clear example of Merck expanding its organizational boundaries while adding value to Mercks operations at the same time. The advantages of Merck & Medco combining together are that
Words: 620 - Pages: 3
Mergers & Acquisitions – Week 3 Scenario Summary This is based on Merck’s Acquisition of Medco: Case 5.1, pp. 124-125. Your Role/Assignment You are the Chairman and CEO of Merck. Make a recommendation to the Board of Directors of Merck & Co. regarding this acquisition based on the recommendations of the three associates and your own analysis. You are the Chairman and Chief Executive Officer of Merck & Company, and you will make the final “yes” or “no” recommendation to the Board of Directors of
Words: 429 - Pages: 2
Walk the Ethical Talk Case Analysis Introduction and situational analysis: In the late 1970’s a disease known as onchocerciasis was running rampant throughout much of Africa and parts of Latin and South America. Onchocerciasis which is also known as “river blindness”, an insect-borne disease, caused by a nematode worm , Onchocerca volvulus affecting both a person’s skin and eyes and is transmitted to humans by the bite of blackflies. Symptoms of this disease range from irritating and intense
Words: 2332 - Pages: 10
Merck & Company Project Selection Decision Introduction As Merck & Company’s lead project manager I have to decide whether to invest its resources in one of two projects. One project is to pursue a cure for river blindness, a disease that has plagued third world countries for a number of years now and the second project is to re-package a very popular and profitable anti-depression drug for the Western market. In this concise report I plan to look at both options through SWOT analysis
Words: 1279 - Pages: 6
probability to be efficacious for depression or weight loss or both indications. Up to now LAB has completed preclinical testing and entering clinical testing. The clinical testing will take about 7 years which is divided into 3 phases. Based on the analysis given on the report, the cost on Phase I will come up to $30 million and the Phase II will be $25 million. The outcome of Phase III varies and depends on the result on Phase II. The expected outcomes are: Davanrik is 10% effective for depression
Words: 1007 - Pages: 5
Business Environment There are many factors a business, such as Merck, must have in order to be successful, for example strong financial statements, leading technology, and globalization. With the help of income statements, balance sheets, and cash flow statements, a financial analysis can be applied in a wide variety of situations to give business managers the information they need to make critical decisions (Financial Analysis, 2010). They also provide information in regards to the financial
Words: 2950 - Pages: 12
TEACHING NOTE – Adapted From Harvard Business School MERCK & COMPANY: Evaluating a Drug Licensing Opportunity Substantive Issues The case explores the valuation of an opportunity to license a compound before it enters clinical trials and describes Merck’s decision tree evaluation process. It also provides information to evaluate a specific licensing opportunity, including the costs of the three phases of the review process, the present value of the revenues associated with successful
Words: 521 - Pages: 3
created by Ralph Potter as an analytical tool assessing the ethics of corporate decision-making, The facts emerging in news accounts regarding lawsuits against the pharmaceutical company Merck and its painkiller Vioxx are analyzed for ethical consideration. Utilizing the Potter Box model, the case against Merck can be interpreted and studied in light of ethical considerations. The results demonstrate not only how a decision is argued, but what is missing in the overall consideration for the decision
Words: 4979 - Pages: 20
How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched
Words: 658 - Pages: 3
Merck: Business Analysis Tamikiia Brown MGT521 July 11, 2011 Sharon Palmitier Merck: Business Analysis Merck is a flourishing research-driven pharmaceutical company, which discovers, develops, manufacturers, and promotes an extensive variety of human and animal health products. Although Merck is one of the biggest pharmaceutical companies of the world, they still come across problems today while striving to sustain a lead against its competition. Merck has achieved success with its lengthy
Words: 1954 - Pages: 8
